Table 4.
Surgical and medical complications of all study groups
| Group 1 | Group 2 | Group 3 | |
|---|---|---|---|
| (N = 126) | (N = 115) | (N = 106) | |
| Postoperative surgical complications | |||
| Wound drainage or delayed healing | 4 (3.1%) | 8 (7.0%) | 5 (4.6%) |
| Arthrofibrosis | 4 (3.1%) | 5 (4.3%) | 5 (4.6%) |
| Patellar crepitus and Clunk syndrome | 2 (1.6% | 0 (0.0%) | 1 (0.9%) |
| Contained hematoma | 1 (0.8%) | 3 (2.6%) | 2 (1.9%) |
| Deep periprosthetic joint infection | 0 (0.0%) | 2 (1.7%) | 2 (1.9%) |
| Femoral aseptic loosening | 2 (1.6%) | 0 (0.0%) | 0 (0.0%) |
| Tibial loosening | 4 (3.1%) | 0 (0%) | 0 (0%) |
| Instability | 1 (0.8%) | 4 (3.5%) | 1 (0.9%) |
| Femoral periprosthetic fracture | 2 (1.6%) | 1 (0.9%) | 0 (0.0%) |
| Patella periprosthetic fracture | 1 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Postoperative medical complications | |||
| Deep vein thrombosis | 3 (2.3%) | 8 (7.0%) | 5 (4.6%) |
| Pulmonary embolism | 3 (2.3%) | 3 (2.6%) | 1 (0.9%) |
| Myocardial infarction | 0 (0.0%) | 0 (0.0%) | 1 (0.9%) |
| Atrial fibrillation | 0 (0.0%) | 1 (0.9%) | 1 (0.9%) |
| Gastrointestinal bleeding | 0 (0.0%) | 0 (0.0%) | 1 (0.9%) |
Group 1 = traditional cemented modular tibia; Group 2 = cemented nonmodular highly porous tibia (as per original FDA approval); Group 3 = uncemented nonmodular highly porous tibia.